tradingkey.logo

Precigen Inc

PGEN
4.290USD
+0.050+1.18%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
1.52BMarktkapitalisierung
VerlustKGV TTM

Precigen Inc

4.290
+0.050+1.18%

mehr Informationen über Precigen Inc Unternehmen

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc Informationen

BörsenkürzelPGEN
Name des UnternehmensPrecigen Inc
IPO-datumAug 08, 2013
CEOSabzevari (Helen)
Anzahl der mitarbeiter143
WertpapierartOrdinary Share
GeschäftsjahresendeAug 08
Addresse20374 Seneca Meadows Parkway
StadtGERMANTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20876
Telefon13015569900
Websitehttps://precigen.com/
BörsenkürzelPGEN
IPO-datumAug 08, 2013
CEOSabzevari (Helen)

Führungskräfte von Precigen Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+557913.00%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+123618.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+116147.00%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+123331.00%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+123618.00%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+15000.00%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
110.60K
-235467.00%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
65.03K
+6000.00%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+557913.00%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+123618.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+116147.00%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+123331.00%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+123618.00%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+15000.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Collaborationandlicensingagreements
1.82M
62.22%
Service
942.00K
32.24%
Product
162.00K
5.54%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Collaborationandlicensingagreements
1.82M
62.22%
Service
942.00K
32.24%
Product
162.00K
5.54%

Aktionärsstatistik

Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
Point72 Asset Management, L.P.
5.17%
William H. Miller III Living Trust
4.91%
Andere
41.57%
Aktionäre
Aktionäre
Anteil
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
Point72 Asset Management, L.P.
5.17%
William H. Miller III Living Trust
4.91%
Andere
41.57%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
35.04%
Investment Advisor
16.54%
Hedge Fund
12.13%
Individual Investor
7.79%
Investment Advisor/Hedge Fund
6.56%
Corporation
5.84%
Research Firm
1.50%
Pension Fund
0.11%
Bank and Trust
0.07%
Andere
14.44%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
319
238.99M
67.55%
+20.23M
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Third Security, LLC
123.95M
35.03%
-4.78M
-3.71%
Nov 21, 2025
Patient Capital Management, LLC
26.46M
7.48%
+10.19M
+62.65%
Sep 30, 2025
Merck Serono SA
20.65M
5.84%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.74M
0.77%
+2.74M
--
Sep 30, 2025
William H. Miller III Living Trust
17.39M
4.91%
+17.39M
--
Jun 26, 2025
Tang Capital Management, LLC
12.40M
3.5%
+12.40M
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.74M
3.03%
+905.62K
+9.21%
Sep 30, 2025
The Vanguard Group, Inc.
8.94M
2.53%
-127.74K
-1.41%
Sep 30, 2025
State Street Investment Management (US)
4.49M
1.27%
+1.46M
+48.22%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.85M
1.09%
+99.56K
+2.66%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Inspire Small/Mid Cap ESG ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
State Street SPDR S&P Biotech ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Mehr Anzeigen
Inspire Small/Mid Cap ESG ETF
Anteil0.24%
ProShares Ultra Nasdaq Biotechnology
Anteil0.14%
iShares Micro-Cap ETF
Anteil0.12%
Invesco Nasdaq Biotechnology ETF
Anteil0.12%
State Street SPDR S&P Biotech ETF
Anteil0.11%
Vanguard US Momentum Factor ETF
Anteil0.1%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.06%
iShares Biotechnology ETF
Anteil0.05%
iShares Russell 2000 Growth ETF
Anteil0.03%
ProShares UltraPro Russell2000
Anteil0.02%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI